{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:11:59Z","timestamp":1776787919568,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172804"],"award-info":[{"award-number":["82172804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04204-y","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:46:26Z","timestamp":1761320786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bispecific antibodies (PD-1\/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy\u00b1bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study"],"prefix":"10.1007","volume":"74","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"4204_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102339","volume":"53","author":"H Fan","year":"2022","unstructured":"Fan H, He Y, Xiang J et al (2022) ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy. Redox Biol 53:102339","journal-title":"Redox Biol"},{"key":"4204_CR2","doi-asserted-by":"crossref","unstructured":"Chuai Y, Wang A, Li Y, Dai G, Zhang X (2019) Anti-angiogenic therapy for persistent, recurrent and metastatic cervical cancer. Cochrane Database Syst Rev 2019:CD013348","DOI":"10.1002\/14651858.CD013348"},{"key":"4204_CR3","first-page":"1","volume":"2023","author":"Y Hu","year":"2023","unstructured":"Hu Y, Li G, Ma Y, Luo G, Wang Q, Zhang S (2023) Effect of exosomal lncRNA MALAT1\/miR-370-3p\/STAT3 positive feedback loop on PI3K\/Akt pathway mediating cisplatin resistance in cervical cancer cells. J Oncol 2023:1\u201316","journal-title":"J Oncol"},{"key":"4204_CR4","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","volume":"27","author":"BJ Monk","year":"2009","unstructured":"Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol: Off J Am Soc Clin Oncol 27:4649\u20134655","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"4204_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","volume":"390","author":"KS Tewari","year":"2017","unstructured":"Tewari KS, Sill MW, Penson RT et al (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240). Lancet 390:1654\u20131663","journal-title":"Lancet"},{"key":"4204_CR6","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D et al (2021) Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 385:1856\u20131867","journal-title":"N Engl J Med"},{"key":"4204_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","volume":"403","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Gladieff L, Mart\u00ednez-Garc\u00eda J et al (2024) Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet (lond Engl) 403:31\u201343","journal-title":"Lancet (lond Engl)"},{"key":"4204_CR8","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","volume":"404","author":"X Wu","year":"2024","unstructured":"Wu X, Sun Y, Yang H et al (2024) Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. Lancet 404:1668\u20131676","journal-title":"Lancet"},{"key":"4204_CR9","doi-asserted-by":"publisher","first-page":"1094437","DOI":"10.3389\/fimmu.2023.1094437","volume":"14","author":"Y Xing","year":"2023","unstructured":"Xing Y, Yasinjan F, Du Y et al (2023) Immunotherapy in cervical cancer: from the view of scientometric analysis and clinical trials. Front Immunol 14:1094437","journal-title":"Front Immunol"},{"key":"4204_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-025-01728-9","volume":"18","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Huang Y, Yang Y et al (2025) Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study. J Hematol Oncol 18:75","journal-title":"J Hematol Oncol"},{"key":"4204_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125838","volume":"26","author":"KS Shan","year":"2025","unstructured":"Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, Dalal M, Ferraro P, Hussein A, Vulfovich M (2025) Bispecific antibodies in solid tumors: advances and challenges. Int J Mol Sci 26:5838","journal-title":"Int J Mol Sci"},{"key":"4204_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong A, Wang L, Chen J et al (2025) Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet 405:839\u2013849","journal-title":"Lancet"},{"key":"4204_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE (2024) The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov 23:301\u2013319","journal-title":"Nat Rev Drug Discov"},{"key":"4204_CR14","first-page":"1","volume":"2022","author":"Z Xu","year":"2022","unstructured":"Xu Z, Yang L, Liu Q, Yu H, Chen L (2022) Machine learning of dose-volume histogram parameters predicting overall survival in patients with cervical cancer treated with definitive radiotherapy. J Oncol 2022:1\u201310","journal-title":"J Oncol"},{"key":"4204_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111578","volume":"129","author":"C Peng","year":"2024","unstructured":"Peng C, Li X, Tang W et al (2024) Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: a multi-center retrospective study. Int Immunopharmacol 129:111578","journal-title":"Int Immunopharmacol"},{"key":"4204_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/10732748251318383","volume":"32","author":"Y Peng","year":"2025","unstructured":"Peng Y, Wu D, Tang J, Li X (2025) Efficacy and safety of anlotinib and PD-1\/L1 inhibitors as maintenance therapy for extensive-stage small cell lung cancer patients who have achieved stable-disease after first-line treatment with chemotherapy and immunotherapy: a retrospective study. Cancer Control 32:10732748251318383","journal-title":"Cancer Control"},{"key":"4204_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00262-025-04038-8","volume":"74","author":"Y Wang","year":"2025","unstructured":"Wang Y, Pan S, Tian J et al (2025) Cadonilimab, a PD-1\/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study. Cancer Immunol Immunother 74:186","journal-title":"Cancer Immunol Immunother"},{"key":"4204_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z et al (2025) First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med 31:1163\u20131170","journal-title":"Nat Med"},{"key":"4204_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359241292264","volume":"16","author":"H Yang","year":"2024","unstructured":"Yang H, Li L, Li X, et al (2024) Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm, prospective phase II trial. Ther Adv Med Oncol 16:1\u201310","journal-title":"Ther Adv Med Oncol"},{"key":"4204_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12916-025-03985-4","volume":"23","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Bei W, Wang L et al (2025) Efficacy and safety of cadonilimab (PD-1\/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial. BMC Med 23:152","journal-title":"BMC Med"},{"key":"4204_CR21","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/1759-7714.15455","volume":"15","author":"H Li","year":"2024","unstructured":"Li H, Zhao W, Li C et al (2024) The efficacy and safety of a novel PD-1\/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: a multicenter retrospective observational study. Thorac Cancer 15:2327\u20132338","journal-title":"Thorac Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04204-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04204-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04204-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T17:20:15Z","timestamp":1763054415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04204-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4204"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04204-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Review Committee of The Affiliated Cancer Hospital of Nanjing Medical University with an approval number of KY-2025\u2013067.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors approved the final version and agreed to be accountable for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}],"article-number":"347"}}